Zevra Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 312.51K shares, a 22174.70% increase year-over-year.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 999.34K shares, a 225.70% increase year-over-year.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 39.75K shares.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 1.40K shares.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 469.56K shares, a 6160.84% increase from fiscal 2023.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 7.50K shares.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 0.00 shares, a 100.00% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-06-30 | 312.51K shares 10-Q · filed 2025-08-12 | |
| 2025-03-31 | 999.34K shares 10-Q · filed 2025-08-12 | |
| 2024-12-31 | 469.56K shares 10-K · filed 2026-03-09 | |
| 2024-09-30 | 39.75K shares 10-Q · filed 2024-11-13 | |
| 2024-06-30 | 1.40K shares 10-Q · filed 2024-11-13 | |
| 2024-03-31 | 306.83K shares 10-Q · filed 2024-11-13 | |
| 2023-12-31 | 7.50K shares 10-K · filed 2025-03-12 | |
| 2023-03-31 | 110.00 shares 10-Q · filed 2023-11-07 | |
| 2022-12-31 | 0.00 shares 10-K · filed 2023-03-07 | |
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-31 | |
| 2020-12-31 | 10.53K shares 10-K · filed 2021-03-12 | |
| 2020-09-30 | 4.47K shares 10-Q · filed 2020-10-30 | |
| 2019-12-31 | 101.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | 101.74K shares 10-K · filed 2020-02-28 |
| 2019-09-30 | 0.00 shares 10-Q · filed 2019-11-14 | 0.00 shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2019-06-30 | 0.00 shares 10-Q · filed 2019-08-13 | 0.00 shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-14 | 22.38K shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | 23.68K shares 10-K · filed 2020-02-28 |
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-14 | 23.68K shares derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | 22.38K shares 10-Q · filed 2019-08-13 | 23.68K shares derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | 1.31K shares 10-Q · filed 2019-05-14 | 11.06K shares derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | 9.75K shares 10-K · filed 2019-03-01 |
| 2017-09-30 | 0.00 shares 10-Q · filed 2018-11-09 | 9.75K shares derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | 9.75K shares 10-Q · filed 2018-08-10 | 24.68K shares derived: sum of 4 quarters · filed 2018-08-10 |
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-11 | 29.87K shares derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | 14.93K shares 10-K · filed 2018-03-30 |
| 2016-09-30 | 14.93K shares 10-Q · filed 2017-11-09 | 33.97K shares derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-06-30 | 14.93K shares 10-Q · filed 2017-08-10 | 19.70K shares derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-03-31 | 0.00 shares 10-Q · filed 2017-05-22 | 4.77K shares derived: sum of 4 quarters · filed 2018-03-30 |
| 2015-12-31 | 4.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | 4.77K shares 10-K · filed 2018-03-30 |
| 2015-09-30 | 666.00 shares 10-Q · filed 2016-11-10 | 666.00 shares derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-08-11 | 0.00 shares derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | 0.00 shares 10-Q · filed 2016-05-13 | 0.00 shares derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | 0.00 shares 10-K · filed 2017-03-10 |
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-11-13 | |
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-08-14 | |
| 2014-03-31 | 0.00 shares 10-Q · filed 2015-05-29 | |
| 2013-12-31 | 0.00 shares 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |